J. Christopher Naftzger, General Counsel and Corporate Secretary at Nabriva Therapeutics plc (NBRV), bought 7,000 shares at $0.59 ($4K) on 2021-12-27, disclosed to the SEC on 2021-12-28.
Open-market purchase of $4k NBRV by General Counsel and Corporate Secretary. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| UNIS | BUY | 2011-03-02 | $14K | — | Filing → |